Lorenzo Pignataro

Background/Objectives: In recent years, the recognition that type 2 inflammation plays a leading role in CRSwNP has enabled the more tailored treatment of the disease through improved patient endotyping. We studied 45 patients with severe CRSwNP who were treated with dupilumab or mepolizumab. The aim was to evaluate the efficacy of these treatments on endoscopic, clinical and patient reported parameters, and to assess whether nasal cytology could be useful for identifying responsive patients and monitoring their response to biologic drugs. Methods: Follow-up visits were scheduled at baseline (T0), and at 3 (T3), 6 (T6), 12 (T12), and 24 months (T24). At each visit, patients underwent blood analysis, nasal endoscopy, and nasal scraping for cytology. They also completed the SNOT-22 questionnaire, a visual analog scale (VAS) for nasal obstruction and smell perception, and the Asthma Control Test (ACT) test in cases of concomitant asthma. Results: Biological therapy demonstrated broad efficacy in disease management, based on both clinical and cytological findings. The Nasal Polyp Score, SNOT-22 questionnaire, VAS scores for nasal obstruction and smell, and ACT score showed progressive improvement. Blood eosinophil counts and total IgE levels also decreased over time (T0 vs. T24: p = 0.008 and p < 0.001, respectively). At nasal cytology, a reduction in eosinophil cell count and in the mixed mast cell–eosinophil pattern during treatment with both biologics were observed (T0 vs. T24: p < 0.001). Positive effects were typically recorded within six months of treatment and were sustained after two years. Conclusions: Although the histological evaluation of infiltrated tissues remains the gold standard for assessing mucosal eosinophilia, nasal cytology appears to be a simpler, non-invasive, and repeatable method for evaluating local eosinophilia. Identifying endotypes and assessing the severity of inflammation are crucial for predicting the efficacy of different treatment options.

IGH and CD79B expression and interaction in HGBCL-DH-BCL2(-BCL6), and relation to follicular lymphoma.

Configuration of IGH, MYC and BCL2 loci in HGBCL-DH-BCL2(-BCL6) and RAG1/2 involvement in t(8;22).

Cytogenetic of COH-DHL1 and COH-THL1 HGBCL-DH-BCL2(-BCL6) cell line models (A-D); In vivo secondary Ighv gene rearrangements in BCR-less murine lambda-MYC lymphomas (E-J)

IGH and CD79B expression, complex formation and IGH isotype choice in DLBCL and HGBCL-DH-BCL2

DLBCL cases included in the study.

Supplementary Table S7 from B-cell Receptor Silencing Reveals the Origin and Dependencies of High-Grade B-cell Lymphomas with MYC and BCL2 Rearrangements

Bulk and spatial gene expression data of MYC and BCL2 dual expressor DLBCL and HGBCL-DH-BCL2 (-BCL6).

Non synonymus SNVs, IGHV gene rearrangements, AID expression status and N-glycosylation motifs in IGHV domains of HGBCL-DH-BCL2(-BCL6).